Durabilityte unveiled a platform aimed at disrupting biologics production using implantable “cell factories”—cells engineered to secrete therapeutic proteins from inside the body. The concept pairs the engineered biology with onboard sensors intended to help clinicians monitor and control production over time. The manufacturing advantage is positioned around bypassing some traditional biologics production complexities, while the monitoring layer is designed to reduce uncertainty in dosing dynamics from implant-based secretion. If clinically validated, the approach could reshape cost structures and logistics for protein therapies. The next gating items will be clinical proof of controlled output, safety over extended durations, and the ability to maintain consistent performance across patient populations.